THE medical revolution that will allow treatment to be tailored to our individual genetic make-up could cost even more than anyone thought. A small Australian biotech company has patents that it claims cover key methods of diagnosing how susceptible an individual is to particular diseases and tailoring drugs to their needs. And it is intent on cashing in on these patents.
Even before researchers had sequenced the human genome, the race had begun to identify the genetic variations that doctors could use to determine whether a particular patient is susceptible to heart disease, say, or whether a particular drug will…
